AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Dec 03, 2018

AbbVie Donates $50 Million To St. Jude Children's Research Hospital® To Expand Family-Centered Care

NORTH CHICAGO, Ill. and MEMPHIS, Tenn., Dec. 3, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced a historic $50 million donation to St. Jude Children's Research Hospital®. This donation will enable St. Jude to accelerate plans to enhance and expand patient and family-centered care at the heart of its mission.

Dec 02, 2018

IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton's Tyrosine Kinase Inhibitor to Date

NORTH CHICAGO, Ill., Dec. 2, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the results of up to seven years of clinical trial follow-up for IMBRUVICA® (ibrutinib) monotherapy in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), the longest follow-up for a Bruton's tyrosine kinase (BTK) inhibitor to date. The updated Phase 1b/2 data demonstrated durable responses in CLL/SLL patients with an overall response rate (ORR) of 89 percent. Evaluated patients included those with high-risk genomic factors such as complex karyotype and unmutated IGHV, and more than 70 patients with three to 12 prior lines of therapy. Progression-free survival (PFS) rates were also sustained (estimated seven-year rates of 80% for previously untreated patients; 32% in the highly pre-treated relapsed/refractory [R/R] groups). The analysis also found that PFS trended better for R/R patients when treated with ibrutinib in earlier lines of therapy (after one or two prior lines of therapy versus three or more lines of prior therapy).

Dec 01, 2018

AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course

NORTH CHICAGO, Ill., Dec. 1, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company today presented updated data from the pivotal Phase 3 MURANO trial of venetoclax (VENCLEXTA® or VENCLYXTO®) in combination with rituximab (VenR). The results at median follow-up of 36 months demonstrated that the majority of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), treated with VenR, did not experience disease progression or death (PFS; the time on treatment without disease progression or death2) after all patients completed the fixed duration of therapy and stopped treatment, compared to patients treated with a standard of care regimen of bendamustine plus rituximab (BR).1 The estimated PFS rate at 36 months was 71.4 percent (95% confidence interval [CI]: 0.64, 0.78) for patients treated with VenR compared with 15.2 percent (95% CI: 0.09, 0.21) for patients who completed treatment with a standard of care combination of BR (hazard ratio [HR]: 0.16; 95% CI: 0.12, 0.23).1 The data were presented today during the 60th American Society of Hematology (ASH) Annual Meeting & Exposition.

Nov 30, 2018

AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Pfizer

NORTH CHICAGO, Ill., Nov. 30, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Pfizer a non-exclusive license on specified dates to AbbVie's intellectual property relating to HUMIRA in the United States and in various other countries around the world in which AbbVie has intellectual property:

Nov 21, 2018

AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

NORTH CHICAGO, Ill., Nov. 21, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA® (venetoclax tablets) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. This indication is approved under accelerated approval based on response rates. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.7

Nov 20, 2018

AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition

NORTH CHICAGO, Ill., Nov. 20, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that data from nearly 40 abstracts, including 13 oral presentations and more than 20 poster presentations, will be presented during the upcoming 60th ASH Annual Meeting & Exposition, December 1-4, in San Diego.

Nov 16, 2018

AbbVie Donates $55 Million to Three Education Nonprofits Supporting Underserved Youth in Chicago & Across America

NORTH CHICAGO, Ill., Nov. 16, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced a $55 million total donation to three leading nonprofits working to address the achievement gap for children in underserved areas: Communities In Schools, City Year and the University of Chicago Education Lab. The donations will grow and strengthen programs focused on improving graduation rates, reducing dropout rates and increasing college and career readiness for children in kindergarten through grade 12 – with an emphasis on children growing up in high-poverty neighborhoods.

Nov 14, 2018

AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress

NORTH CHICAGO, Ill., Nov. 14, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today presented for the first time additional results from two replicate pivotal Phase 3 clinical trials (ELARIS UF-1 (M12-815) and ELARIS UF-2 (M12-817)) evaluating the efficacy and safety of elagolix in women with uterine fibroids.  These results were presented at the 47th American Association of Gynecologic Laparoscopists (AAGL) Global Congress on Minimally Invasive Gynecology in Las Vegas, NV.

Nov 13, 2018

AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

NORTH CHICAGO, Ill., Nov. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data for its pan-genotypic chronic hepatitis C virus (HCV) treatment, MAVYRET™ (glecaprevir/pibrentasvir), in treatment-naïve patients with compensated cirrhosis. Results from the Phase 3b EXPEDITION-8 study showed that with 8 weeks of MAVYRET, 100 percent (n=273/273) of genotype 1, 2, 4, 5 and 6 patients achieved a sustained virologic response 12 weeks after treatment (SVR12) per protocol analysis.1

Nov 13, 2018

AbbVie to Present at the Evercore ISI Conference

NORTH CHICAGO, Ill., Nov. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Evercore ISI HealthConX Conference on Tuesday, November 27, 2018. Bill Chase, executive vice president, finance and administration, will present at 8 a.m. Eastern time.